S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:AUTL

Autolus Therapeutics Competitors

$6.19
-0.01 (-0.16 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.65
Now: $6.19
$6.38
50-Day Range
$6.20
MA: $7.67
$9.11
52-Week Range
$3.00
Now: $6.19
$17.19
Volume913,417 shs
Average Volume919,236 shs
Market Capitalization$323.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75

Competitors

Autolus Therapeutics (NASDAQ:AUTL) Vs. PCVX, CHRS, CRTX, TSHA, ADVM, and MESO

Should you be buying AUTL stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Autolus Therapeutics, including Vaxcyte (PCVX), Coherus BioSciences (CHRS), Cortexyme (CRTX), Taysha Gene Therapies (TSHA), Adverum Biotechnologies (ADVM), and Mesoblast (MESO).

Vaxcyte (NASDAQ:PCVX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Insider and Institutional Ownership

74.1% of Vaxcyte shares are held by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Vaxcyte and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Autolus Therapeutics$2.91 million111.14$-123,850,000.00($2.88)-2.15

Vaxcyte has higher earnings, but lower revenue than Autolus Therapeutics.

Profitability

This table compares Vaxcyte and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vaxcyte and Autolus Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Autolus Therapeutics01702.88

Vaxcyte presently has a consensus target price of $48.00, indicating a potential upside of 102.02%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Vaxcyte.

Summary

Vaxcyte beats Autolus Therapeutics on 6 of the 9 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

22.9% of Autolus Therapeutics shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Coherus BioSciences and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$356.07 million3.24$89.83 million$1.2312.87
Autolus Therapeutics$2.91 million111.14$-123,850,000.00($2.88)-2.15

Coherus BioSciences has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coherus BioSciences and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences33.06%90.98%27.33%
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Volatility and Risk

Coherus BioSciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Coherus BioSciences and Autolus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01402.80
Autolus Therapeutics01702.88

Coherus BioSciences presently has a consensus target price of $26.50, indicating a potential upside of 67.40%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Coherus BioSciences.

Summary

Coherus BioSciences beats Autolus Therapeutics on 8 of the 14 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

55.5% of Cortexyme shares are owned by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Cortexyme and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A$-36,980,000.00($1.94)-19.58
Autolus Therapeutics$2.91 million111.14$-123,850,000.00($2.88)-2.15

Cortexyme has higher earnings, but lower revenue than Autolus Therapeutics. Cortexyme is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cortexyme and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CortexymeN/A-37.78%-35.24%
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Volatility and Risk

Cortexyme has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cortexyme and Autolus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cortexyme21402.29
Autolus Therapeutics01702.88

Cortexyme presently has a consensus target price of $50.00, indicating a potential upside of 31.61%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Cortexyme.

Summary

Cortexyme beats Autolus Therapeutics on 7 of the 13 factors compared between the two stocks.

Taysha Gene Therapies (NASDAQ:TSHA) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

42.2% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Taysha Gene Therapies and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene TherapiesN/AN/AN/AN/AN/A
Autolus Therapeutics$2.91 million111.14$-123,850,000.00($2.88)-2.15

Taysha Gene Therapies has higher earnings, but lower revenue than Autolus Therapeutics.

Profitability

This table compares Taysha Gene Therapies and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taysha Gene TherapiesN/AN/AN/A
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Taysha Gene Therapies and Autolus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taysha Gene Therapies00603.00
Autolus Therapeutics01702.88

Taysha Gene Therapies presently has a consensus target price of $40.3333, indicating a potential upside of 37.38%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Taysha Gene Therapies.

Summary

Taysha Gene Therapies beats Autolus Therapeutics on 5 of the 8 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

97.4% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are owned by institutional investors. 12.4% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Adverum Biotechnologies and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,349.97$-64,490,000.00($1.01)-11.01
Autolus Therapeutics$2.91 million111.14$-123,850,000.00($2.88)-2.15

Adverum Biotechnologies has higher earnings, but lower revenue than Autolus Therapeutics. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adverum Biotechnologies and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Volatility and Risk

Adverum Biotechnologies has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Adverum Biotechnologies and Autolus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Autolus Therapeutics01702.88

Adverum Biotechnologies presently has a consensus target price of $23.50, indicating a potential upside of 111.33%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Adverum Biotechnologies.

Summary

Adverum Biotechnologies beats Autolus Therapeutics on 9 of the 14 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Volatility and Risk

Mesoblast has a beta of 3.71, indicating that its share price is 271% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mesoblast and Autolus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
Autolus Therapeutics01702.88

Mesoblast presently has a consensus target price of $14.55, indicating a potential upside of 58.67%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Mesoblast.

Valuation & Earnings

This table compares Mesoblast and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39
Autolus Therapeutics$2.91 million111.14$-123,850,000.00($2.88)-2.15

Mesoblast has higher revenue and earnings than Autolus Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mesoblast and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Insider & Institutional Ownership

2.8% of Mesoblast shares are owned by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Mesoblast beats Autolus Therapeutics on 8 of the 14 factors compared between the two stocks.


Autolus Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PCVX
Vaxcyte
1.8$23.76-0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83-3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99-4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36-20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12-1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17-0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56-17.2%$1.02 billionN/A-5.87News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39-0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83-2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10-5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75-2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41-3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80-3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11-3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13-2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19-6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02-1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76-1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54-2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18-0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20-1.3%$608.48 million$150.05 million-2.94
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.50-4.2%$603.52 million$22.24 million-5.72Upcoming Earnings
Analyst Report
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21-3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$12.60-9.1%$571.96 million$147.87 million-4.19Analyst Upgrade
News Coverage
Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$9.40-6.1%$568.22 millionN/A-4.56Upcoming Earnings
News Coverage
Gap Up
Compugen logo
CGEN
Compugen
1.4$8.30-1.6%$567.54 million$17.80 million-22.42Analyst Downgrade
High Trading Volume
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.56-4.5%$559.28 million$13.29 million-10.33Upcoming Earnings
News Coverage
Gap Up
Curis logo
CRIS
Curis
1.3$9.47-3.6%$557.00 million$10 million-11.55Increase in Short Interest
Gap Up
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.3$21.00-2.7%$544.11 millionN/A-6.05
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$8.63-7.5%$533.51 millionN/A-1.26Upcoming Earnings
High Trading Volume
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.57-0.1%$512.46 million$4.36 million-4.74Upcoming Earnings
Increase in Short Interest
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.25-1.6%$469.42 millionN/A0.00Upcoming Earnings
HARP
Harpoon Therapeutics
1.5$17.65-8.4%$447.96 million$5.78 million-8.29Upcoming Earnings
News Coverage
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$11.32-6.9%$412.63 millionN/A-3.43Gap Up
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
Opthea logo
OPT
Opthea
1.5$9.11-2.6%$384.55 millionN/A0.00Decrease in Short Interest
Gap Down
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.72-5.6%$360.15 million$250,000.00-3.47Analyst Revision
Gap Up
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.68-1.3%$354.47 millionN/A0.00Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.31-0.2%$340.41 million$96.12 million-12.68Upcoming Earnings
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.55-2.2%$336.45 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Gap Up
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.75-1.1%$333.15 millionN/A-5.86High Trading Volume
Decrease in Short Interest
News Coverage
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.14-4.5%$332.32 millionN/A0.00Upcoming Earnings
Analyst Upgrade
Gap Down
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.82-0.5%$315.65 million$8.15 million-1.46Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.50-0.4%$305.08 million$15.36 million-11.36Upcoming Earnings
Gap Down
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.71-1.5%$295.46 millionN/A0.00Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.08-1.8%$295.39 millionN/A-3.74Upcoming Earnings
Gap Down
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.27-4.0%$281.35 million$4.13 million-5.04News Coverage
Gap Up
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.80-3.8%$259.79 millionN/A-7.88Gap Up
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.64-2.6%$242.85 millionN/A-4.77Analyst Report
News Coverage
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.